Hematology最新文献_第9页

XPO1 Inhibition enhances sensitivity to platinum-based chemotherapy in germinal-center B-cell-like-DLBCL cells. XPO1抑制增强生发中心b细胞样dlbcl细胞对铂基化疗的敏感性。

IF 2 4区医学

Hematology Pub Date : 2026-12-01 Epub Date: 2026-02-03 DOI: 10.1080/16078454.2026.2619209

Qiongqiong Su, Xiaolei Wei, Yongqiang Wei, Ru Feng

{"title":"XPO1 Inhibition enhances sensitivity to platinum-based chemotherapy in germinal-center B-cell-like-DLBCL cells.","authors":"Qiongqiong Su, Xiaolei Wei, Yongqiang Wei, Ru Feng","doi":"10.1080/16078454.2026.2619209","DOIUrl":"10.1080/16078454.2026.2619209","url":null,"abstract":"Purpose: Platinum-based chemotherapy is considered as salvage therapy to relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients. However, treatment failure due to drug resistance occurs in some patients, particularly those with Exportin 1 (XPO1) overexpression. This study investigates whether XPO1 inhibition enhances platinum sensitivity in DLBCL subtypes.Methods: XPO1 expression in DLBCL was predicted using online datasets. Cell lines representing DLBCL subtypes were treated with varying concentrations of the XPO1 inhibitor selinexor (XPO1i), cisplatin (CDDP), and oxaliplatin (OXA), alone or in combination. Cellular viability was assessed via CCK-8 assay, while apoptosis rates and reactive oxygen species (ROS) levels were measured by flow cytometry. Protein levels of XPO1 and pro-apoptotic cytokines were evaluated using Western blotting.Results: Bioinformatic analysis revealed elevated XPO1 expression in DLBCL. Both XPO1i and platinum-based therapy inhibited cellular viability and promoted apoptosis across DLBCL subtypes in a dose-dependent fashion. The combination of XPO1i at its IC50 and CDDP synergistically suppressed cell viability across both activated B-cell-like- and germinal-center B-cell-like (GCB)-DLBCL subtypes compared to CDDP monotherapy. The combination of XPO1i at its IC30 and OXA synergistically led to a greater reduction in cell viability, along with enhanced induction of apoptosis and ROS accumulation in GCB-DLBCL cells. In OCI-Ly8 and OCI-Ly1 cells, OXA alone inhibited phosphorylation of AKT and mTOR while increasing phosphorylation of JNK, ATM, and p53, and expression of γH2AX; these effects were potentiated by the combination of XPO1i and OXA.Conclusion: XPO1 inhibition enhances platinum-induced cytotoxicity in GCB-DLBCL, supporting clinical evaluation of XPO1i-platinum combinations as salvage therapy.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2619209"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146105242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics and prognosis of Epstein Barr virus-positive diffuse large B-cell lymphoma: a retrospective, single-center study. eb病毒阳性弥漫性大b细胞淋巴瘤的特点和预后：一项回顾性单中心研究

IF 2 4区医学

Hematology Pub Date : 2026-12-01 Epub Date: 2026-02-11 DOI: 10.1080/16078454.2026.2621541

Lin Qiaochu, Liao Lianming, Shen Jianzhen, Luo XiaoFeng, Fu Haiying, Liu Tingbo

{"title":"Characteristics and prognosis of Epstein Barr virus-positive diffuse large B-cell lymphoma: a retrospective, single-center study.","authors":"Lin Qiaochu, Liao Lianming, Shen Jianzhen, Luo XiaoFeng, Fu Haiying, Liu Tingbo","doi":"10.1080/16078454.2026.2621541","DOIUrl":"10.1080/16078454.2026.2621541","url":null,"abstract":"Objective: To analyze the clinical characteristics and prognosis of Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+DLBCL) in a Chinese cohort.Methods: Fifty-seven EBV+DLBCL patients (diagnosed between 2013 and 2020) and 228 EBV-negative DLBCL (EBV-DLBCL) controls were included. Differences were compared and prognostic factors were identified using univariate and multivariate analysis.Results: EBV+DLBCL patients (median age, 56 years; 38 men [66.7%]) predominantly had non-GCB origin (70.2%). Compared with EBV-DLBCL, EBV+DLBCL patients more frequently presented with B symptoms, hypoalbuminemia, anemia, >1 extranodal site involvement, and elevated LDH andβ2-microglobulin (all P < 0.05). The common extranodal sites were the digestive tract (stomach), nasopharynx, bone marrow, and bone. CD30 positivity was higher in EBV+DLBCL patients (42.1% vs. controls, P < 0.001). After R-CHOP-like therapy, EBV+DLBCL patients achieved complete and overall response rates of 55.5% (30/54) and 83.3% (45/54), respectively. With a median follow-up period of 28 months, the relapse rate was 22.2% (10/45). The response and relapse rates were similar between groups. Multivariate analysis identified elevatedβ2-microglobulin and bone marrow invasion as independent risk factors for worse progression-free survival (PFS), and elevatedβ2-microglobulin plus decreased hemoglobin for worse overall survival (OS) in EBV+DLBCL.Conclusion: EBV+ DLBCL in this Chinese cohort was primarily non-GCB. Elevatedβ2-microglobulin and bone marrow invasion independently predicted inferior PFS, while elevatedβ2-microglobulin and anemia predicted inferior OS.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2621541"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146157313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification and functional exploration of hub genes related to energy metabolism in acute myeloid leukemia. 急性髓性白血病能量代谢相关枢纽基因的鉴定与功能探索。

IF 2 4区医学

Hematology Pub Date : 2026-12-01 Epub Date: 2026-03-02 DOI: 10.1080/16078454.2026.2637350

Yi Chen, Yueru Ji, Weiwei Qin, Xueqian Yan

{"title":"Identification and functional exploration of hub genes related to energy metabolism in acute myeloid leukemia.","authors":"Yi Chen, Yueru Ji, Weiwei Qin, Xueqian Yan","doi":"10.1080/16078454.2026.2637350","DOIUrl":"10.1080/16078454.2026.2637350","url":null,"abstract":"Objectives: Acute myeloid leukemia (AML) is an aggressive hematological malignancy with poor prognosis. Abnormal energy metabolism is a well-recognized cancer hallmark, yet the role of energy metabolism-related genes (EMRGs) in AML remains unclear. Thus, this study aims to identify such hub genes in AML and explore their prognostic significance, related pathways, and therapeutic targeting potential.Methods: AML-related datasets and EMRGs were obtained from public databases. The hub gene was identified through differential expression analysis, correlation analysis and PPI analysis, etc. Then, a set enrichment analysis was conducted. A drug-gene network was constructed, and immune microenvironment analysis was performed.Results: In this study, six hub genes (CDH1, AGRN, NDST3, GPC3, CD44, and COL4A1) were identified, and their expression levels were significantly associated with the overall survival of AML patients. These hub genes also exhibited significant expression differences among clusters; for instance, CD44 was upregulated in cluster 2, while COL4A1 and GPC3 were downregulated. Functional enrichment analysis showed that they were associated with 'ribosome', ECM-receptor interaction', and other functional pathways. Consequently, lapatinib, gentamicin, etc., were predicted based on the hub genes, and we found that CDH1 was positively correlated with multiple cells, such as NK cells and T cells, and there was the highest positive correlation between CDH1 and NK cells.Discussion: AML shows a poor response to chemotherapy. Six hub genes linked to metabolism, pathways (ribosome, immune, NOD), and drug targets (e.g. Lapatinib/CDH1) were identified. Correlation of CDH1 with NK cells is discussed.Conclusion: These hub genes offer promising targets for future individualized AML therapy.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2637350"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147325306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world clinical outcomes and treatment response in complement inhibitor experienced and naïve PNH patients prescribed pegcetacoplan in Europe and Canada. 在欧洲和加拿大，补体抑制剂经历和naïve PNH患者服用pegcetacoplan的实际临床结果和治疗反应。

IF 1.6 4区医学

Hematology Pub Date : 2026-12-01 Epub Date: 2026-01-02 DOI: 10.1080/16078454.2025.2608510

Jens Panse, Juan Carlos Vallejo Llamas, Koo Wilson, Zalmai Hakimi, Barbara Czech, Brianne Kerr, Sam Williamson, Yasmin Taylor, Niall Hatchell, Christopher J Patriquin

{"title":"Real-world clinical outcomes and treatment response in complement inhibitor experienced and naïve PNH patients prescribed pegcetacoplan in Europe and Canada.","authors":"Jens Panse, Juan Carlos Vallejo Llamas, Koo Wilson, Zalmai Hakimi, Barbara Czech, Brianne Kerr, Sam Williamson, Yasmin Taylor, Niall Hatchell, Christopher J Patriquin","doi":"10.1080/16078454.2025.2608510","DOIUrl":"10.1080/16078454.2025.2608510","url":null,"abstract":"Objectives: This study investigated outcomes and response to pegcetacoplan in complement inhibitor naïve (CInaïve) and experienced (CIexp) PNH patients.Methods: Data were drawn from the Adelphi PNH Disease Specific Programme™, a cross-sectional survey of physicians and their patients in Canada, France, Germany, Italy, Spain, and the UK between December 2023 and April 2024. Physicians reported patient characteristics and clinical outcomes, which were used to define pegcetacoplan response. Results were stratified by prior CI prescription. Analyses were descriptive.Results: Forty-eight physicians reported on 63 patients (CInaïve:11; CIexp:52). Median (IQR) age was 45.0 (33.0-55.0) years, 60.3% were male. At treatment initiation versus at survey for CInaïve and CIexp, respectively, median (IQR) haemoglobin levels (g/dL) were 8.0 (5.0-9.0) versus 12.0 (11.2-12.3), and 9.0 (8.0-9.2) versus 11.0 (10.2-12.0); lactate dehydrogenase levels (U/L) were 500 (350-1625) versus 250 (175-525), and 470 (290-588) versus 265 (190-379); absolute reticulocyte counts (x109 /L) were 220 (151-250) versus 110 (95-140), and 212 (134-281) versus 120 (105-228). At pegcetacoplan initiation, 4.4% of patients met criteria of good-to-complete response versus 79.5% at survey.Conclusions: Pegcetacoplan proved effective for CInaïve and CIexp patients in a real-world setting, with numerically improved clinical outcomes and high response rate.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2608510"},"PeriodicalIF":1.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and mechanism of action of sovleplenib for aplastic anemia. 索来普利尼治疗再生障碍性贫血的疗效及作用机制。

IF 2 4区医学

Hematology Pub Date : 2026-12-01 Epub Date: 2026-02-03 DOI: 10.1080/16078454.2026.2618419

Tianzi Sheng, Wei Sun, Shan Xin, Chengcheng Zhou, Hong Liu

{"title":"Efficacy and mechanism of action of sovleplenib for aplastic anemia.","authors":"Tianzi Sheng, Wei Sun, Shan Xin, Chengcheng Zhou, Hong Liu","doi":"10.1080/16078454.2026.2618419","DOIUrl":"10.1080/16078454.2026.2618419","url":null,"abstract":"Objective: This study aimed to investigate the therapeutic potential of sovleplenib, a selective SYK inhibitor, in aplastic anemia (AA), focusing on its effects on immune modulation and the cGAS-STING-NF-κB inflammatory axis.Methods: An immune-mediated AA mouse model was established and treated with sovleplenib. Hematopoietic function was assessed via peripheral blood counts and bone marrow mononuclear cell (BMNC) counts. Immune cell profiles were analyzed by flow cytometry. Cytokine levels were measured by ELISA. Underlying mechanisms were explored through proteomics and Western blotting.Results: Sovleplenib treatment significantly improved peripheral blood counts (HGB, WBC, PLT) and BMNCs, and reduced bone marrow fat vacuolation. It corrected immune imbalance by increasing the CD4+/CD8+ T-cell ratio and decreasing the M1/M2 macrophage ratio, promoting an M2 phenotype. Concurrently, it elevated Arg-1 level while suppressing ROS, TNF-α, and IFN-β. Mechanistically, sovleplenib inhibited the activation of key pathway components (cGAS, STING, p-TBK1, p-p65).Discussion: The results demonstrate sovleplenib's dual role in promoting hematopoiesis and immunomodulation. Its efficacy is mechanistically linked to the suppression of the overactivated cGAS-STING-NF-κB pathway, a key driver of inflammation in AA.Conclusion: Sovleplenib represents a promising targeted therapy for AA.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2618419"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146105316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria. 阵发性夜间血红蛋白尿患者从克罗伐单抗转为伊普他科泮后贫血和症状的改善

IF 2 4区医学

Hematology Pub Date : 2026-12-01 Epub Date: 2026-01-29 DOI: 10.1080/16078454.2026.2620152

Daisuke Ogiya, Sawako Shiraiwa, Seina Koyama, Motoki Endo, Shunsuke Tomita, Miina Nasukawa, Masako Toyosaki, Shinichiro Machida, Makoto Onizuka, Yoshiaki Ogawa, Hiroshi Kawada

{"title":"Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria.","authors":"Daisuke Ogiya, Sawako Shiraiwa, Seina Koyama, Motoki Endo, Shunsuke Tomita, Miina Nasukawa, Masako Toyosaki, Shinichiro Machida, Makoto Onizuka, Yoshiaki Ogawa, Hiroshi Kawada","doi":"10.1080/16078454.2026.2620152","DOIUrl":"10.1080/16078454.2026.2620152","url":null,"abstract":"Objectives: Paroxysmal nocturnal hemoglobinuria (PNH) may develop breakthrough hemolysis (BTH) despite C5 inhibition. Although iptacopan, an oral factor B inhibitor, has demonstrated efficacy in phase 3 trials, switching from crovalimab has not been reported. We describe the first clinical case of this switch in a real-world clinical setting.Methods: A 72-year-old man with long-standing PNH received eculizumab followed by crovalimab. Infectious enteritis triggered BTH and worsening anemia during crovalimab therapy. Because anemia persisted after recovery, iptacopan 200 mg twice daily was initiated three weeks after the final crovalimab administration. Clinical symptoms and laboratory parameters were followed for 12 months. This case report complied with the Declaration of Helsinki.Results: Hemoglobin increased from 9.6 to 11.6 g/dL within two weeks and remained ≥12 g/dL thereafter. Dyspnea resolved within one week, vitality improved by two weeks, and no BTH or treatment-related adverse events occurred during follow-up.Discussion: This case demonstrates the feasibility of switching from crovalimab to iptacopan despite the absence of an established method, and pharmacokinetic considerations guided the timing.Conclusion: Switching to iptacopan led to rapid and durable improvement in anemia and symptoms, supporting proximal complement inhibition as a valuable option for PNH patients inadequately controlled with C5 inhibitors.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2620152"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Propofol and/or etomidate-induced immune thrombocytopenia: A case report. 异丙酚和/或依托咪酯诱导的免疫性血小板减少症1例报告。

IF 2 4区医学

Hematology Pub Date : 2026-12-01 Epub Date: 2026-02-28 DOI: 10.1080/16078454.2026.2638607

Kai Wang, Ye Jing Shen, Hong Biao Zheng

{"title":"Propofol and/or etomidate-induced immune thrombocytopenia: A case report.","authors":"Kai Wang, Ye Jing Shen, Hong Biao Zheng","doi":"10.1080/16078454.2026.2638607","DOIUrl":"10.1080/16078454.2026.2638607","url":null,"abstract":"Objective: To report a case of severe immune-mediated thrombocytopenia highly suspected to be induced by propofol and/or etomidate.Clinical features: A 62-year-old female patient developed acute, severe thrombocytopenia following two separate general anesthesia events in 2025. The first episode occurred 14 days after laparoscopic renal cyst unroofing, with a platelet nadir of 1 × 10⁹/L. The second episode occurred 11 days after painless gastroscopy and colonoscopy, with a platelet nadir of 2 × 10⁹/L. Platelet counts normalized after treatment with glucocorticoids, thrombopoietin receptor agonists, and platelet transfusions on both occasions. We suspect that propofol and/or etomidate, common drugs used in both anesthesia procedures, induced immune-mediated thrombocytopenia.Conclusion: Propofol and/or etomidate may induce immune-mediated thrombocytopenia. Anesthesiologists should enhance their awareness of this rare adverse reaction. When unexplained thrombocytopenia occurs post-anesthesia, besides common causes like sepsis, DIC, or heparin-induced thrombocytopenia, propofol and/or etomidate induced thrombocytopenia must be considered as an important differential diagnosis.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2638607"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between red cell distribution width to albumin ratio and all-cause mortality in critically ill patients with myelodysplastic syndrome: a retrospective cohort study. 骨髓增生异常综合征危重患者红细胞分布宽度与白蛋白比与全因死亡率之间的关系：一项回顾性队列研究

IF 2 4区医学

Hematology Pub Date : 2026-12-01 Epub Date: 2026-03-17 DOI: 10.1080/16078454.2026.2642448

Zicong Huang, Shan Liu, Zhi Guo

{"title":"Association between red cell distribution width to albumin ratio and all-cause mortality in critically ill patients with myelodysplastic syndrome: a retrospective cohort study.","authors":"Zicong Huang, Shan Liu, Zhi Guo","doi":"10.1080/16078454.2026.2642448","DOIUrl":"10.1080/16078454.2026.2642448","url":null,"abstract":"Background: The red cell distribution width to albumin ratio (RAR) has emerged as a novel, easily calculated biomarker demonstrating prognostic value across various diseases. However, the relationship of RAR for all-cause mortality risk in critically ill patients with myelodysplastic syndromes (MDS) remains unclear.Objectives: To explore the association between RAR and all-cause mortality in critically ill patients with MDS.Methods: This retrospective cohort study utilized patient data from the MIMIC-IV database. The study population was patients with MDS admitted to ICU for the first time. The main outcome was all-cause mortality at 28-day, 90-day, and 365-day. The association between RAR and all-cause mortality was evaluated using Cox proportional hazards regression analysis. Restricted Cubic Spline (RCS) regression was employed to test for any non-linear relationship between RAR levels and the mortality risk.Results: Patients in the high RAR group showed significantly worse survival rates across time points of 28-day, 90-day, and 365-day compared to the low RAR group (log-rank test, all P < 0.001). In the adjusted multivariable Cox regression model, elevated RAR as a continuous variable was significantly associated with an increased risk of all-cause mortality: 28-day (HR = 1.18; 95% CI: 1.08-1.29; P < 0.001), 90-day (HR = 1.18; 95% CI: 1.09-1.27; P < 0.001), and 365-day (HR = 1.17; 95% CI: 1.10-1.25; P < 0.001). RCS analysis confirmed a positive but non-linear association between increasing RAR levels and heightened mortality risk.Conclusions: RAR, a readily available composite biomarker, is associated with all-cause mortality in critically ill patients with MDS.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2642448"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cyclosporine A improves survival in lower-risk hypoplastic myelodysplastic syndromes: a single-center retrospective study from China. 环孢素A可提高低危性骨髓增生不良综合征患者的生存率：一项来自中国的单中心回顾性研究

IF 1.6 4区医学

Hematology Pub Date : 2026-12-01 Epub Date: 2025-12-18 DOI: 10.1080/16078454.2025.2605379

Yumei Liu, Liyan Yang, Yansong Wei, Wei Zhang, Huijuan Jiang, Lijuan Li, Limin Xing, Zonghong Shao, Rong Fu, Huaquan Wang

{"title":"Cyclosporine A improves survival in lower-risk hypoplastic myelodysplastic syndromes: a single-center retrospective study from China.","authors":"Yumei Liu, Liyan Yang, Yansong Wei, Wei Zhang, Huijuan Jiang, Lijuan Li, Limin Xing, Zonghong Shao, Rong Fu, Huaquan Wang","doi":"10.1080/16078454.2025.2605379","DOIUrl":"https://doi.org/10.1080/16078454.2025.2605379","url":null,"abstract":"Background: Hypoplastic myelodysplastic syndrome (hMDS) is an uncommon MDS subtype, accounting for approximately 10-15% of cases, characterized by bone marrow hypocellularity, severe cytopenias, and features of immune dysregulation. Its clinical course overlaps with aplastic anemia, yet optimal management for lower-risk patients remains undefined, particularly in Asian populations.Methods: We retrospectively analyzed 48 patients with lower-risk hMDS (IPSS-R very low/low/intermediate) treated at Tianjin Medical University General Hospital from 2013 to 2021. Patients received cyclosporine A (CsA, n = 16), hypomethylating agents (HMAs, n = 10), low-dose HMAs (LD-HMAs, n = 11), or best supportive care (BSC, n = 11). Responses were assessed by modified IWG criteria, and survival was evaluated by Kaplan-Meier and Cox regression analyses.Results: Median age was 61 years (range 16-84), with 60.4% male. Somatic mutations were present in 64.6%, and PNH clones in 29.2%. Six-month overall response rates were 75.0% for CsA, 70.0% for HMAs, 54.5% for LD-HMAs, and 36.4% for BSC (p = 0.220). CsA achieved significantly longer complete remission (median 75 months) and hematologic improvement durations (p < 0.05). Median overall survival (OS)/progression-free survival (PFS) for CsA were 78.0/76.0 months, compared with 17.0/6.8 for HMAs, 31.0/15.0 for LD-HMAs, and 36.0/15.0 for BSC (p < 0.01). HMAs were associated with increased grade 3-4 infections.Conclusion: CsA provides superior response durability, survival outcomes, and safety compared with other approaches, supporting its use as first-line therapy in lower-risk hMDS. Integration of immune and molecular profiling may refine individualized treatment strategies.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2605379"},"PeriodicalIF":1.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145774651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronotype and sleep duration in relation to leukaemia subtypes: a two-sample Mendelian randomization analysis. 时间型和睡眠时间与白血病亚型的关系：两样本孟德尔随机化分析。

IF 2 4区医学

Hematology Pub Date : 2026-12-01 Epub Date: 2026-02-13 DOI: 10.1080/16078454.2026.2626211

Lina Wang, Jiang Liu, Jiahui Liu, Ling Zhang, Ruijuan Zhang

{"title":"Chronotype and sleep duration in relation to leukaemia subtypes: a two-sample Mendelian randomization analysis.","authors":"Lina Wang, Jiang Liu, Jiahui Liu, Ling Zhang, Ruijuan Zhang","doi":"10.1080/16078454.2026.2626211","DOIUrl":"10.1080/16078454.2026.2626211","url":null,"abstract":"Objectives: Several observational studies have suggested an association between sleep traits and leukaemia. This study aimed to determine the causal association between sleep traits and leukaemia using two-sample Mendelian Randomization (MR) analysis.Methods: Publicly available databases were used to retrieve summary statistics from genome-wide association studies (GWAS) related to sleep traits (UK BioBank) and leukaemia (FinnGen database). Inverse Variance Weighted (IVW) method was utilized for the primary MR analysis. Subsequently, we conducted a reverse MR analysis. Sensitivity analyses and statistical power calculation validated the robustness of the research findings. The Steiger directionality test was employed to ascertain the direction of causality.Results: Univariable MR identified nominal associations between chronotype and higher risk of acute lymphoblastic leukaemia (OR = 2.15, P = 0.014) and chronic myeloid leukaemia (OR = 1.27, P = 0.016), as well as between short sleep duration and lower lymphoid leukaemia risk (OR = 0.06, P = 0.035). However, none remained significant after FDR correction. Sensitivity analyses revealed no evidence of heterogeneity or horizontal pleiotropy. Adjusting for smoking and BMI in multivariable MR abolished all associations. Colocalization suggested shared genetic variants, but reverse MR indicated a significant effect only from acute lymphoblastic leukaemia to chronotype (PFDR = 0.0017).Conclusions: Our MR study found several nominal associations that sleep traits causally influence leukaemia subtypes. Nominal associations were not significant after multiple testing correction, attenuated by adjustment for smoking and BMI, and potentially affected by pleiotropy or reverse causation.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"31 1","pages":"2626211"},"PeriodicalIF":2.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146179309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0